Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype-phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.

Authors

Institutions

Publication Details

Journal
British Journal of Dermatology
Published
2025-04-04
DOI
https://doi.org/10.1093/bjd/ljaf123
Citations
29
Primary Topic
Skin and Cellular Biology Research
Type
article
Field-Weighted Citation Impact
33.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

Á. Hernández‐Martín, Joyce Teng, Alain Hovnanian, Amy S. Paller et al.
29 citations
British Journal of Dermatology
Skin and Cellular Biology Research
33.39
article

Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

Á. Hernández‐Martín, Joyce Teng, Alain Hovnanian, Amy S. Paller, Gianluca Tadini, Judith Fischer, Eli Sprecher, Kiril Malovitski, Akemi Ishida‐Yamamoto, J. Mazereeuw‐Hautier, Keith A. Choate, Matthias Schmuth, Antoni Gostyński, Céline Granier Tournier, Edel A. O’Toole, Masashi Akiyama, Christine Bodemer, Mandy Aldwin-Easton, Schwartz Janice
article en
29 citations

Abstract

Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype-phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.

British Journal of DermatologyVol. 193(4)
Northwestern University (US), Hôpital Necker-Enfants Malades (FR), Lurie Children's Hospital (US), Université Toulouse III - Paul Sabatier (FR), Asahikawa Medical University (JP), Inserm (FR), University of Freiburg (DE), Tel Aviv University (IL), Queen Mary University of London (GB), University of Milan (IT), Université Paris Cité (FR), Tel Aviv Sourasky Medical Center (IL), Maastricht University Medical Centre (NL), University Medical Center Freiburg (DE), University Medical Center (US), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Yale University (US), Maastricht University (NL), Institut Necker Enfants Malades (FR), Assistance Publique – Hôpitaux de Paris (FR), Endometriosis UK (GB), Hospital Infantil Universitario Niño Jesús (ES), Lurie Children's Hospital (US), Karl Landsteiner Society (AT), Institut des Maladies Génétiques Imagine (FR), Pachyonychia Congenita Project (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Nagoya University (JP), Stanford University (US)
Foundation for Ichthyosis and Related Skin Types, Incyte, Amryt Pharma, Austrian Science Fund, Daiichi-Sankyo, Novo Nordisk, LEO Fondet, LEO Pharma
Good health and well-being
Openalex Percentile: Top 0%
Skin and Cellular Biology Research
33.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.